{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:02:25Z","timestamp":1789470145129,"version":"build-2803163510"},"reference-count":201,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple myeloma (MM) is an incurable malignancy and ranks as the second most common hematological cancer in western countries. Relapsed disease is common in MM patients, and is largely influenced by the establishment of an immunosuppressive tumor microenvironment (TME) and concomitant systemic immune impairment. Myeloid-derived suppressor cells (MDSCs) are crucial regulators of immune homeostasis and response in various pathological states, including cancer. Within the TME, MDSCs and tumor cells engage in bidirectional crosstalk through both direct and indirect mechanisms, collectively driving immune evasion and tumor progression. As a principal immunosuppressive population within the MM milieu, MDSCs play a central role in the immunoregulation of MM. Although immunotherapy has emerged as a pivotal treatment modality for MM, MDSCs, the key constituents of the TME, constitute a major source of resistance to such therapies. This review elucidates the mechanisms governing MDSCs interactions within the myeloma TME, discusses potential therapeutic strategies targeting MDSCs, and outlines a rational framework for integrating MDSC-directed approaches with current MM therapies and immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1815669","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:04:15Z","timestamp":1789466655000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Myeloid-derived suppressor cells in multiple myeloma: mechanistic insights and therapeutic implications"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingjing","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation","place":["Mianyang, Sichuan, China"]},{"name":"Department of Hematology\/Institute of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaolin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Institute of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147627","article-title":"Targeting the microenvironment for treating multiple myeloma","volume":"23","author":"Neumeister","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garcia-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169541","article-title":"Therapeutic strategies to enhance immune response induced by multiple myeloma cells","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-023-00475-8","article-title":"Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in hematological Malignancies","volume":"11","author":"Wang","year":"2023","journal-title":"biomark Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346211","article-title":"Different evasion strategies in multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133213","article-title":"Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities","volume":"13","author":"Botta","year":"2021","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1102471","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016059","article-title":"The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers","volume":"13","author":"Fan","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/life14040461","article-title":"Role of immune cells and immunotherapy in multiple myeloma","volume":"14","author":"Radhakrishnan","year":"2024","journal-title":"Life (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","article-title":"The terminology issue for myeloid-derived suppressor cells","volume":"67","author":"Gabrilovich","year":"2007","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903573","article-title":"CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice","volume":"185","author":"Haile","year":"2010","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-019-0797-3","article-title":"Myeloid-derived suppressor cells in hematological Malignancies: Friends or foes","volume":"12","author":"Lv","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01062-0","article-title":"Defining myeloid-derived suppressor cells","volume":"24","author":"Akkari","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.04.002","article-title":"Myeloid-derived suppressor cells: The green light for myeloma immune escape","volume":"30","author":"Malek","year":"2016","journal-title":"Blood Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.599098","article-title":"Actors on the scene: Immune cells in the myeloma niche","volume":"10","author":"Leone","year":"2020","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1646-4","article-title":"Tumor-induced CD14+HLA-DR (-\/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000045588","article-title":"Detection and clinical significance of peripheral blood myeloid-derived suppressor cells in patients with multiple myeloma","volume":"104","author":"Chen","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204717","article-title":"Increased monocytic myeloid-derived suppressor cells in whole blood predict poor prognosis in patients with plasma cell myeloma","volume":"10","author":"Bae","year":"2021","journal-title":"J Clin Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26362","article-title":"Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation","volume":"10","author":"Tyrinova","year":"2024","journal-title":"Heliyon"},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40425-018-0491-y","article-title":"Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"7","author":"Lee","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7969","article-title":"Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)","volume":"7","author":"Giallongo","year":"2016","journal-title":"Oncotarget"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01301-6","article-title":"Targeting LAG3\/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma","volume":"36","author":"Bae","year":"2022","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-019-1011-5","article-title":"Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation","volume":"18","author":"Ai","year":"2019","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1470929","article-title":"PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy","volume":"18","author":"Romano","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1861-2","article-title":"Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory\/relapsed multiple myeloma","volume":"65","author":"Lee","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2025.2585083","article-title":"Functional role of granulocytic myeloid-derived suppressor cells in CAR-T therapy: Insights from single-cell RNA sequencing in multiple myeloma","volume":"47","author":"Zhang","year":"2025","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7150\/jca.29647","article-title":"Increased circulating grmyeloid-derived suppressor cells correlated with tumor burden and survival in locally advanced cervical cancer patient","volume":"10","author":"Liang","year":"2019","journal-title":"J Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/nyas.12469","article-title":"Myeloid-derived suppressor cell heterogeneity in human cancers","volume":"1319","author":"Solito","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70660","article-title":"Circulating M-MDSC expansion during therapy associates with treatment response in multiple myeloma: A longitudinal observational study","volume":"19","author":"Yan","year":"2026","journal-title":"Clin Transl Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"Condamine","year":"2011","journal-title":"Trends Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00172","article-title":"MDSCs: Key criminals of tumor pre-metastatic niche formation","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.11.014","article-title":"Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor","volume":"117","author":"Li","year":"2020","journal-title":"Mol Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2006.12.012","article-title":"CCL2\/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers","volume":"252","author":"Huang","year":"2007","journal-title":"Cancer Lett"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.10.009","article-title":"CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis","volume":"24","author":"Katoh","year":"2013","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.367","article-title":"CXCL2\/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer","volume":"36","author":"Katoh","year":"2017","journal-title":"Oncogene"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081120","article-title":"Cancer-derived VEGF-C increases chemokine production in lymphatic endothelial cells to promote CXCR2-dependent cancer invasion and MDSC recruitment","volume":"11","author":"Chen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0348","article-title":"CCR5(+) myeloid-derived suppressor cells are enriched and activated in melanoma lesions","volume":"78","author":"Blattner","year":"2018","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2020.23.e26","article-title":"Myeloid-derived suppressor cells recruited by chemokine (C-C motif) ligand 3 promote the progression of breast cancer via phosphoinositide 3-kinase-protein kinase B-mammalian target of rapamycin signaling","volume":"23","author":"Luo","year":"2020","journal-title":"J Breast Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101089","article-title":"Non-redundant roles of the CCR1 and CCR2 chemokine axes in monocyte recruitment during lung metastasis","volume":"59","author":"Liner","year":"2025","journal-title":"Neoplasia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: Molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Cambier","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215598","article-title":"PMN-MDSCs accumulation induced by CXCL1 promotes CD8(+) T cells exhaustion in gastric cancer","volume":"532","author":"Zhou","year":"2022","journal-title":"Cancer Lett"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.02.008","article-title":"Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma","volume":"15","author":"Mosevoll","year":"2013","journal-title":"Cytotherapy"},{"key":"B51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12964-024-01544-7","article-title":"Research progress of the chemokine\/chemokine receptor axes in the oncobiology of multiple myeloma (MM)","volume":"22","author":"Du","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172888","article-title":"The importance of chemokines activating CXCR1, CXCR2 and CXCR3 in tumorigenesis as potential therapeutic targets in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"17","author":"Korbecki","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/MOH.0000000000000389","article-title":"The regulation and importance of monocyte chemoattractant protein-1","volume":"25","author":"Bianconi","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41419-019-2012-4","article-title":"CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma","volume":"10","author":"Xu","year":"2019","journal-title":"Cell Death Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26245","article-title":"The MIP-1alpha autocrine loop contributes to decreased sensitivity to anticancer drugs","volume":"233","author":"Tsubaki","year":"2018","journal-title":"J Cell Physiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.27879","article-title":"Heme oxygenase-1 attenuates the inhibitory effect of bortezomib against the APRIL-NF-kappaB-CCL3 signaling pathways in multiple myeloma cells: Corelated with bortezomib tolerance in multiple myeloma","volume":"120","author":"He","year":"2019","journal-title":"J Cell Biochem"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286484","article-title":"A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma","volume":"110","author":"Anloague","year":"2025","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16881","article-title":"Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma","volume":"191","author":"Kuwahara-Ota","year":"2020","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.08.034","article-title":"Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma","volume":"56","author":"Pappa","year":"2011","journal-title":"Cytokine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1747-x","article-title":"Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-alpha in multiple myeloma","volume":"35","author":"Pappa","year":"2014","journal-title":"Tumour Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287312","article-title":"Macrophages promote aberrant DNA repair in multiple myeloma via the CXCL5\/8-CXCR2 axis","volume":"111","author":"Dong","year":"2026","journal-title":"Haematologica"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07413-6","article-title":"Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK\/STAT3 pathway","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030321","article-title":"Bone marrow CX3CL1\/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients","volume":"11","author":"Marchica","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.3941","article-title":"Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments","volume":"33","author":"Wada","year":"2015","journal-title":"Oncol Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041185","article-title":"The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity","volume":"200","author":"Nie","year":"2004","journal-title":"J Exp Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284443","article-title":"A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma","volume":"109","author":"Sabol","year":"2024","journal-title":"Haematologica"},{"key":"B68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41389-022-00380-z","article-title":"CXCL12\/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment","volume":"11","author":"Giallongo","year":"2022","journal-title":"Oncogenesis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13045-022-01366-5","article-title":"CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression","volume":"15","author":"Beider","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2019.4344","article-title":"Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13","volume":"20","author":"Zhang","year":"2020","journal-title":"Bosn J Basic Med Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.dci.2003.09.010","article-title":"Regulation of myeloid development and function by colony stimulating factors","volume":"28","author":"Barreda","year":"2004","journal-title":"Dev Comp Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/eji.200939903","article-title":"Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF","volume":"40","author":"Dolcetti","year":"2010","journal-title":"Eur J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000901","article-title":"Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells","volume":"185","author":"Lechner","year":"2010","journal-title":"J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2013.06.006","article-title":"Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor\/c-met and STAT3","volume":"1","author":"Yen","year":"2013","journal-title":"Stem Cell Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-016-0822-9","article-title":"Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer","volume":"39","author":"Ko","year":"2016","journal-title":"Arch Pharm Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01929.x","article-title":"GM-CSF and IL-12 production by Malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model","volume":"129","author":"Galea","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155271","article-title":"Cytokine profile in multiple myeloma","volume":"136","author":"Jasrotia","year":"2020","journal-title":"Cytokine"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2135-z","article-title":"Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies","volume":"73","author":"Guillerey","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0578","article-title":"Mediators of inflammation-driven expansion, trafficking, and function of tumor-infiltrating MDSCs","volume":"7","author":"Tannenbaum","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100587","article-title":"HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment","volume":"207","author":"Corzo","year":"2010","journal-title":"J Exp Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0782-x","article-title":"Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift","volume":"38","author":"Park","year":"2019","journal-title":"Oncogene"},{"key":"B82","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/0008-5472.CAN-13-1196","article-title":"Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population","volume":"74","author":"Laoui","year":"2014","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194688","article-title":"PYK2\/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma","volume":"104","author":"Muz","year":"2019","journal-title":"Haematologica"},{"key":"B84","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","article-title":"Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination","volume":"34","author":"Garces","year":"2020","journal-title":"Leukemia"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01590-8","article-title":"Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma","volume":"40","author":"Xu","year":"2021","journal-title":"Oncogene"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108571","article-title":"Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer","volume":"33","author":"Kwak","year":"2020","journal-title":"Cell Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74056","article-title":"ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis","volume":"124","author":"Condamine","year":"2014","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86641","article-title":"Associations between myeloid-derived suppressor cells, TIM-3+ T cells, and clinical factors during the post-transplant neutropenia period in patients with multiple myeloma","volume":"17","author":"Batorov","year":"2025","journal-title":"Cureus"},{"key":"B90","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170762","article-title":"Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target","volume":"133","author":"Ozbay Kurt","year":"2023","journal-title":"J Clin Invest"},{"key":"B92","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/0008-5472.CAN-09-2587","article-title":"Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine","volume":"70","author":"Srivastava","year":"2010","journal-title":"Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03070","article-title":"Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma","volume":"10","author":"Siret","year":"2019","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.11.062","article-title":"Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-beta during murine colitis","volume":"17","author":"Lee","year":"2016","journal-title":"Cell Rep"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1413520","article-title":"A novel MDSC-induced PD-1(-)PD-L1(+) B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties","volume":"7","author":"Shen","year":"2018","journal-title":"Oncoimmunology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.CAN-09-1882","article-title":"Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer","volume":"70","author":"Pan","year":"2010","journal-title":"Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01242","article-title":"PD\/1-PD-Ls checkpoint: insight on the potential role of NK cells","volume":"10","author":"Pesce","year":"2019","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1047580","article-title":"Anergic bone marrow Vgamma9Vdelta2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma","volume":"4","author":"Castella","year":"2015","journal-title":"Oncoimmunology"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41467-017-00784-1","article-title":"Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes","volume":"8","author":"Zhu","year":"2017","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-006700","article-title":"The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function","volume":"108","author":"Della Chiesa","year":"2006","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138581","article-title":"Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer","volume":"5","author":"Ugolini","year":"2020","journal-title":"JCI Insight"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0397-9","article-title":"S100A9-induced overexpression of PD-1\/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes","volume":"33","author":"Cheng","year":"2019","journal-title":"Leukemia"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1209821","article-title":"Pivotal advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE(2) catabolism in myeloid cells","volume":"88","author":"Eruslanov","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","article-title":"Immune checkpoint inhibitors for multiple myeloma immunotherapy","volume":"12","author":"Liu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283344","article-title":"Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients","volume":"109","author":"Ninkovic","year":"2024","journal-title":"Haematologica"},{"key":"B109","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12943-025-02460-1","article-title":"Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.12.010","article-title":"Small-molecule agents for cancer immunotherapy","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104254","article-title":"IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy","volume":"359","author":"Weber","year":"2021","journal-title":"Cell Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3300","article-title":"Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells","volume":"6","author":"De Veirman","year":"2015","journal-title":"Oncotarget"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.14473","article-title":"Single-cell transcriptome analysis reveals the effect of MIF on myeloid-derived suppressor cells in multiple myeloma","volume":"47","author":"Zhao","year":"2025","journal-title":"Int J Lab Hematol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.141683","article-title":"CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma","volume":"6","author":"Lewinsky","year":"2021","journal-title":"JCI Insight"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0663","article-title":"Myeloma-secreted galectin-1 potently interacts with CD304 on monocytic myeloid-derived suppressor cells","volume":"9","author":"Lim","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1158\/2326-6066.CIR-21-0242","article-title":"Galectin-1 supports a dangerous liaison between monocytes and multiple myeloma","volume":"9","author":"Ugel","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19049","article-title":"Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma","volume":"203","author":"Mizuhara","year":"2023","journal-title":"Br J Haematol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/path.4712","article-title":"Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression","volume":"239","author":"Wang","year":"2016","journal-title":"J Pathol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/jim-2019-001010","article-title":"Multiple myeloma-derived exosomes inhibit osteoblastic differentiation and improve IL-6 secretion of BMSCs from multiple myeloma","volume":"68","author":"Liu","year":"2020","journal-title":"J Investig Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-018-0614-4","article-title":"Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC","volume":"11","author":"Piddock","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6083","article-title":"The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285099","article-title":"LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma","volume":"109","author":"Gong","year":"2024","journal-title":"Haematologica"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0284","article-title":"Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sites","volume":"80","author":"Xu","year":"2020","journal-title":"Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"key":"B126","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.11.002","article-title":"Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway","volume":"442","author":"De Veirman","year":"2019","journal-title":"Cancer Lett"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0192","article-title":"Extracellular S100A9 protein in bone marrow supports multiple myeloma survival by stimulating angiogenesis and cytokine secretion","volume":"5","author":"De Veirman","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.691705","article-title":"S100A9 derived from myeloma associated myeloid cells promotes TNFSF13B\/TNFRSF13B-dependent proliferation and survival of myeloma cells","volume":"11","author":"Meng","year":"2021","journal-title":"Front Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9270","article-title":"Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma","volume":"7","author":"Binsfeld","year":"2016","journal-title":"Oncotarget"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008979","article-title":"Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors","volume":"13","author":"Xiong","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0240","article-title":"Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma","volume":"7","author":"Lee-Chang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B134","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41419-021-03745-1","article-title":"Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1(-)PD-L1(+) Bregs through PD-L1\/PI3K\/AKT\/NF-kappaB axis in breast cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048871","article-title":"Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells","volume":"7","author":"Zhuang","year":"2012","journal-title":"PloS One"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0310","article-title":"Runx2 deficiency in osteoblasts promotes myeloma resistance to bortezomib by increasing TSP-1-dependent TGFbeta1 activation and suppressing immunity in bone marrow","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275375","article-title":"Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer","volume":"14","author":"Bazargan","year":"2023","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.21.9291","article-title":"Gemcitabine in treating patients with refractory or relapsed multiple myeloma","volume":"15","author":"Zheng","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178617","article-title":"Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells","volume":"134","author":"Shen","year":"2024","journal-title":"J Clin Invest"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020274","article-title":"Nanoparticles dual targeting both myeloma cells and cancer-associated fibroblasts simultaneously to improve multiple myeloma treatment","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001278","article-title":"A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)","volume":"4","author":"Lancet","year":"2020","journal-title":"Blood Adv"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1784","article-title":"Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody","volume":"23","author":"Dominguez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.12.026","article-title":"LXR\/ApoE activation restricts innate immune suppression in cancer","volume":"172","author":"Tavazoie","year":"2018","journal-title":"Cell"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2018.1509201","article-title":"The success and the challenge of all-trans retinoic acid in the treatment of cancer","volume":"59","author":"Ni","year":"2019","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3415","article-title":"Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy","volume":"78","author":"Bauer","year":"2018","journal-title":"Cancer Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281339","article-title":"All-trans retinoic acid works synergistically with the gamma-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells","volume":"108","author":"Garcia-Guerrero","year":"2023","journal-title":"Haematologica"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105557","article-title":"1alpha, 25 dihydroxyvitamin D (1,25(OH)(2)D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC)","volume":"198","author":"Fleet","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/nu16010142","article-title":"Vitamin D and K supplementation is associated with changes in the methylation profile of U266-multiple myeloma cells, influencing the proliferative potential and resistance to bortezomib","volume":"16","author":"Luczkowska","year":"2023","journal-title":"Nutrients"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1177\/10815589241249998","article-title":"Prevalence, outcomes, and complications of vitamin D deficiency among patients with multiple myeloma: Nationwide burden of disease","volume":"72","author":"Gujarathi","year":"2024","journal-title":"J Investig Med"},{"key":"B152","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41408-024-01046-2","article-title":"In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease","volume":"14","author":"Lund","year":"2024","journal-title":"Blood Cancer J"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1178-0","article-title":"Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth","volume":"61","author":"Porembka","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042168","article-title":"CXCR2 receptor: Regulation of expression, signal transduction, and involvement in cancer","volume":"23","author":"Korbecki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B155","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nrc3893","article-title":"S100 proteins in cancer","volume":"15","author":"Bresnick","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005319","article-title":"Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma","volume":"11","author":"Fan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137482","article-title":"A phase 1 study of tasquinimod in patients with relapsed or refractory multiple myeloma","volume":"136","author":"Vogl","year":"2020","journal-title":"Blood"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.7555","article-title":"Clinical activity of novel targeting of S100A9 with tasquinimod for relapsed and refractory multiple myeloma (RRMM)","volume":"43","author":"Vogl","year":"2025","journal-title":"J Clin Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23062919","article-title":"The rationale for the dual-targeting therapy for RSK2 and AKT in multiple myeloma","volume":"23","author":"Isa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2534","article-title":"Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3Kdelta\/gamma","volume":"77","author":"Davis","year":"2017","journal-title":"Cancer Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/cells11060941","article-title":"Biological hallmarks and emerging strategies to target STAT3 signaling in multiple myeloma","volume":"11","author":"Zhou","year":"2022","journal-title":"Cells"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8311","article-title":"Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: An opportunity for cancer therapy","volume":"7","author":"Dufait","year":"2016","journal-title":"Oncotarget"},{"key":"B164","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004384","article-title":"STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice","volume":"10","author":"Bitsch","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617699","article-title":"Inhibition of arginase 1 liberates potent T cell immunostimulatory activity of human neutrophil granulocytes","volume":"11","author":"Vonwirth","year":"2020","journal-title":"Front Immunol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"19660","DOI":"10.1038\/s41598-022-24137-1","article-title":"Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity","volume":"12","author":"Ramji","year":"2022","journal-title":"Sci Rep"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J Exp Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0213","article-title":"Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma","volume":"2","author":"Noonan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v122.21.1959.1959","article-title":"Administration of an oral PDE5 inhibitor, tadalafil in conjunction with a lenalidomide containing regimen in patients with multiple myeloma","volume":"122","author":"Ghosh","year":"2013","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3055","article-title":"COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells","volume":"71","author":"Fujita","year":"2011","journal-title":"Cancer Res"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-021-00590-4","article-title":"COX2 confers bone marrow stromal cells to promoting TNFalpha\/TNFR1beta-mediated myeloma cell growth and adhesion","volume":"44","author":"Kuang","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0457","article-title":"IDO vaccine ablates immune-suppressive myeloid populations and enhances antitumor effects independent of tumor cell IDO status","volume":"10","author":"Nandre","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B174","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: Mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2790-6","article-title":"Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment","volume":"145","author":"Zhou","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0062-8","article-title":"Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors","volume":"32","author":"Bae","year":"2018","journal-title":"Leukemia"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20220309-00165","article-title":"Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)","volume":"61","year":"2022","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01370","article-title":"Lenalidomide and programmed death-1 blockade synergistically enhances the effects of dendritic cell vaccination in a model of murine myeloma","volume":"9","author":"Vo","year":"2018","journal-title":"Front Immunol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013623","article-title":"Alliance A061202: Ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse","volume":"8","author":"Voorhees","year":"2024","journal-title":"Blood Adv"},{"key":"B180","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00262-025-04247-1","article-title":"Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid Malignancies","volume":"75","author":"Zhou","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","volume":"35","author":"Casneuf","year":"2021","journal-title":"Leukemia"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1814253","article-title":"CD38: Targeted therapy in multiple myeloma and therapeutic potential for solid cancers","volume":"29","author":"Jiao","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760382","article-title":"Dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma","volume":"11","author":"Uckun","year":"2021","journal-title":"Front Oncol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061353","article-title":"Immune system alterations in multiple myeloma: Molecular mechanisms and therapeutic strategies to reverse immunosuppression","volume":"13","author":"Diaz-Tejedor","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2020.131","article-title":"A novel anti-PD-L1 antibody exhibits antitumor effects on multiple myeloma in murine models via antibody-dependent cellular cytotoxicity","volume":"29","author":"Ahn","year":"2021","journal-title":"Biomol Ther (Seoul)"},{"key":"B189","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clml.2020.08.008","article-title":"Daratumumab with cetrelimab, an anti-PD-1 monoclonal antibody, in relapsed\/refractory multiple myeloma","volume":"21","author":"Cohen","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26333","article-title":"Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma","volume":"96","author":"Biran","year":"2021","journal-title":"Am J Hematol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123615","article-title":"Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial","volume":"12","author":"Puig","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0043-z","article-title":"Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma","volume":"3","author":"Jing","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B194","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s40425-019-0764-0","article-title":"34th annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2019): Part 2 : National Harbor, MD, USA. 10 November 2019","volume":"7","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B195","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s13046-023-02845-4","article-title":"Amino acid metabolism reprogramming: Shedding new light on T cell anti-tumor immunity","volume":"42","author":"Zheng","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-25-4817","article-title":"The conflicting role of myeloid cells in CAR T-cell therapy","volume":"86","author":"DeFranco","year":"2026","journal-title":"Cancer Res"},{"key":"B198","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-025-01745-8","article-title":"Genome-edited allogeneic CAR-T cells: The next generation of cancer immunotherapies","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011768","article-title":"Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance","volume":"13","author":"Ponzo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.08.025","article-title":"MDSC targeting with gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers","volume":"47","author":"Fultang","year":"2019","journal-title":"EBioMedicine"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5848","article-title":"CD38BiTE-secretion overcomes antigen escape in BCMA-targeted CAR T cell therapy for multiple myeloma","volume":"146","author":"Jianlin","year":"2025","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815669\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:04:19Z","timestamp":1789466659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815669\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":201,"alternative-id":["10.3389\/fimmu.2026.1815669"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1815669","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1815669"}}